How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Plasma Fibrinogen Market
- By Product Type: Cryoprecipitate, Fibrinogen Concentrate, Plasma-derived Fibrinogen, Recombinant Fibrinogen
- By Application: Hemophilia Treatment, Trauma and Surgery, Liver Disease Management, Obstetrics and Gynecology, Cardiovascular Disorders
- By End User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Research Institutes
- By Formulation: Lyophilized Powder, Liquid Formulation
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cryoprecipitate leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the Blood Plasma Fibrinogen Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Application 5
End User 4
Formulation 2
Companies profiled
CSL Behring
Grifols
Octapharma
Baxter International
Kedrion Biopharma
LFB Group
SanguiBio
Haema AG
Biotest AG
Mitsubishi Tanabe Pharma Corporation
Shanghai RAAS Blood Products
China Biologic Products Holdings
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CSL Behring
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Grifols
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Octapharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Baxter International
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Kedrion Biopharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LFB Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →SanguiBio
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Haema AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Biotest AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Shanghai RAAS Blood Products
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →China Biologic Products Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bharat Serums and Vaccines
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sanquin
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bio Products Laboratory
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$2,936M by 2033 · 5.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cryoprecipitate62.7
- Fibrinogen Concentrate10.8
- Plasma-derived Fibrinogen14.7
- Recombinant Fibrinogen11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$646.2M → $888.6M · 4.1%
Europe$450.4M → $606.8M · 3.8%
Asia Pacific$411.2M → $675.9M · 6.4%
Latin America$254.6M → $411.8M · 6.2%
Middle East and Africa$195.8M → $304.6M · 5.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.142026
5.162027
5.172028
5.172029
5.192030
5.212031
5.212032
5.232033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CSL Behring11.7
- Grifols20.7
- Octapharma8.8
- Baxter International9.7
- Kedrion Biopharma13.8
- LFB Group7.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type31.8%
Application28.4%
End User25.4%
Formulation14.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.8
- Europe21.0
- Asia Pacific23.4
- Latin America14.3
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CSL Behring | 76 | 88 | 96 | 82 | 86 | 98 | 88 |
| Grifols | 81 | 85 | 76 | 84 | 91 | 71 | 81 |
| Octapharma | 86 | 67 | 79 | 65 | 69 | 68 | 72 |
| Baxter International | 65 | 63 | 75 | 62 | 74 | 74 | 69 |
| Kedrion Biopharma | 61 | 69 | 73 | 65 | 74 | 60 | 67 |
| LFB Group | 69 | 55 | 59 | 71 | 53 | 65 | 62 |
| SanguiBio | 48 | 52 | 64 | 41 | 50 | 64 | 53 |
| Haema AG | 45 | 51 | 42 | 41 | 53 | 36 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CSL Behring
- Grifols
- Octapharma
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CSL Behring | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Grifols | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Octapharma | ◐ | ◐ | ✓ | − | ◐ | − |
| Baxter International | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Kedrion Biopharma | ◐ | ✓ | ◐ | ◐ | ◐ | − |
| LFB Group | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| SanguiBio | ◐ | − | − | − | − | ◐ |
| Haema AG | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CSL Behring88
2Grifols81
3Octapharma72
4Baxter International69
5Kedrion Biopharma67
6LFB Group62
7SanguiBio53
8Haema AG45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CSL BehringGrifols
Challenger3
Strong scale, closing on the leaders.
OctapharmaBaxter InternationalKedrion Biopharma
Contender1
Focused players with pockets of strength.
LFB Group
Niche2
Specialists in a single segment or region.
SanguiBioHaema AG
Go-to-market strategy
Land Product Type in North America, then scale across Blood Plasma Fibrinogen Market — a $538M beachhead inside a $10.5B market.
Beachhead (SOM)$538Mobtainable near-term
Serviceable (SAM)$3.75Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Cryoprecipitate
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Fibrinogen Concentrate
Strong fit — clear ROI and a fast path to value.
End user67 fit
Plasma-derived Fibrinogen
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Plasma Fibrinogen Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation13%
Closed-won6%
$14.4KCAC
$51KLTV
3.5:1LTV : CAC
< 2 moCAC payback
Investment thesis
Blood Plasma Fibrinogen Market is a high-growth opportunity — $1.36B by 2033, compounding at 11.3%.
TAM · 2025$580Mtoday
TAM · 2033$1.36Bforecast
CAGR11.3%2027–2033
Cumulative$8.31Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.36BTotal addressable market
SAM$513MServiceable available market
SOM$92MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.36BLarge & growingTAM by 2033 at 11.3% CAGR
$513MServiceable nowreachable with today’s model
$92MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.06BBear7.3% CAGR
$1.36BBase11.3% CAGR
$1.75BBull14.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Plasma Fibrinogen Market — a $5.33B market by 2033. Plan: grow share from 10.7% to 16.8%.
Market size · 2033$5.33Btotal addressable
Market CAGR9.2%2027–2033
Target share16.8%from 10.7% today
Revenue ambition$896Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.7% | 16.8% | On track |
| Revenue | $565M | $896M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 28.6% | 45.1% | At risk |
| Customer retention | 90.6% | 93.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $103M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Blood Plasma Fibrinogen Market conversation — a $7.36B market you can size, segment and defend in minutes.
Market size · 2033$7.36Btotal opportunity
Growth11.5%CAGR to 2033
Addressable buyers1,642+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 3 mopayback period
$78K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
CSL BehringGrifolsOctapharmaBaxter InternationalKedrion BiopharmaLFB GroupSanguiBioHaema AG+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Plasma Fibrinogen Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Plasma Fibrinogen Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Plasma Freezer Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBlood Platelet Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBlood Pressure Kiosk Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBlood Pressure Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportBlood Pressure Monitor Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBlood Pressure Monitoring Sensors Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportBlood Pressure Sensor Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBlood Pressure Transducer Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBlood Processing Consumables (CH 5) Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBlood Processing Equipments Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBlood Procurement Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBlood Purification Tubing Set Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.